https://www.selleckchem.com/pr....oducts/Obatoclax-Mes
BACKGROUND Incidence of extraskeletal osteosarcoma (ESOS) is extremely low and the prognosis remains unclear. We conducted this study to explore prognostic factors and the role of chemotherapy in ESOS. MATERIAL AND METHODS We screened data from the Surveillance Epidemiology and End Results (SEER) database (1975-2016). Three hundred ten patients with ESOS were included and 49.4% (107/31 of them underwent chemotherapy. We performed logistic regression analysis to investigate potential factors determining selection of chemothe
Like
Comment
Share
